|Mr. Vincent P. Ippolito
|MD & Executive Chairman
|Dr. Howie McKibbon
|Chief Executive Officer
|Mr. Matthew Callahan L.L.B., M.B.A., MBA LLB
|Dr. Jack Hoblitzell Ph.D.
|Senior Vice President of Pharmaceutical Development
|Dr. Patricia S. Walker M.D., Ph.D.
|Chief Medical Adviser
|Ms. Susan Patricia Park A.C.A., A.C.I.S., ACSA, AGIA, B.Com., F Fin, FCIS
Botanix Pharmaceuticals Limited engages in the research and development of dermatology and antimicrobial products in Australia. The company engages in development of novel treatments for common skin diseases and infections. Its product pipeline includes Sofpironium Bromide, a drug in development for the treatment of primary axillary hyperhidrosis that has completed Phase 3 clinical programs; BTX 1503, a transdermal gel formulation for the treatment of serious acne in adults and teenagers that has completed Phase II clinical trials; BTX 1801, which has completed Phase IIb clinical trials for the treatment of staphylococcus aureus and methicillin resistant staphylococcus aureus; BTX 1702 that is in Phase II clinical trials for the treatment of papulopustular rosacea; and BTX 1204A for the treatment of atopic dermatitis. Botanix Pharmaceuticals Limited was incorporated in 1984 and is based in Leederville, Australia.
Botanix Pharmaceuticals Limited’s ISS governance QualityScore as of N/A is N/A. The pillar scores are Audit: N/A; Board: N/A; Shareholder rights: N/A; Compensation: N/A.